View in EDS HTML Full Text PDF Full Text

Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?

Saved in:
Bibliographic Details
Title: Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
Authors: Beijert IJ; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., Hentschel AE; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., Bründl J; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Compérat EM; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France., Plass K; European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands., Rodríguez O; Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain., Subiela Henríquez JD; Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain., Hernández V; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain., de la Peña E; Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain., Alemany I; Pathology, Hospital Universitario Fundación Alcorcón, Madrid, Spain., Turturica D; Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy., Pisano F; Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.; Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy., Soria F; Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy., Čapoun O; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic., Bauerová L; Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic., Pešl M; Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic., Bruins HM; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Radboud University Medical Center, Nijmegen, The Netherlands.; Urology, Zuyderland Medical Center, Sittard/Heerlen, The Netherlands., Runneboom W; Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Herdegen S; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Breyer J; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Brisuda A; Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic., Calatrava A; Pathology, Fundación Instituto Valenciano de Oncología (I.V.O.), Valencia, Spain., Rubio-Briones J; Urology, Fundación Instituto Valenciano de Oncología (I.V.O.), Valencia, Spain., Seles M; Urology, Medical University of Graz, Graz, Austria., Mannweiler S; Pathology, Medical University of Graz, Graz, Austria., Bosschieter J; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., Kusuma VRM; Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK., Ashabere D; Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK., Huebner N; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria., Cotte J; Urology, Pitié Salpétrière Hospital, AP-HP, GRC no 5, ONCOTYPE-URO, Sorbonne University, 75013, Paris, France., Contieri R; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Mertens LS; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Claps F; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Masson-Lecomte A; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands., Liedberg F; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands., Cohen D; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, UK., Lunelli L; Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France., Cussenot O; Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France., El Sheikh S; Pathology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, UK., Volanis D; Urology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, UK., Côté JF; Pathology, Pierre et Marie Curie Medical School, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France., Rouprêt M; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Pitié Salpétrière Hospital, AP-HP, GRC no 5, ONCOTYPE-URO, Sorbonne University, 75013, Paris, France., Haitel A; Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria., Shariat SF; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria., Mostafid AH; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK., Nieuwenhuijzen JA; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., Zigeuner R; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Medical University of Graz, Graz, Austria., Dominguez-Escrig JL; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Fundación Instituto Valenciano de Oncología (I.V.O.), Valencia, Spain., Hacek J; Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic., Zlotta AR; Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada., Burger M; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands., Evert M; Pathology, University of Regensburg, Regensburg, Germany., Hulsbergen-van de Kaa CA; Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., van der Heijden AG; Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Kiemeney LALM; Health Evidence and Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Soukup V; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic., Molinaro L; Pathology, Città della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy., Gontero P; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy., Llorente C; Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain., Algaba F; Pathology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain., Palou J; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain., N'Dow J; European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands., Ribal MJ; European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands., van der Kwast TH; Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada., Babjuk M; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria., Sylvester RJ; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands., van Rhijn BWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. b.v.rhijn@nki.nl.; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. b.v.rhijn@nki.nl.; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. b.v.rhijn@nki.nl.; Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. b.v.rhijn@nki.nl.
Source: International urology and nephrology [Int Urol Nephrol] 2024 Apr; Vol. 56 (4), pp. 1323-1333. Date of Electronic Publication: 2023 Nov 19.
Publication Type: Journal Article
Journal Info: Publisher: Springer Country of Publication: Netherlands NLM ID: 0262521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2584 (Electronic) Linking ISSN: 03011623 NLM ISO Abbreviation: Int Urol Nephrol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1573-2584
DOI:10.1007/s11255-023-03867-9